Search Results - "Burman CF"

Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.

Authors: Martínez-Puig, Pablo Báez-Gutiérrez, Nerea Rodríguez-Ramallo, Héctor et al.

Source: PLoS ONE. 2/12/2025, Vol. 20 Issue 2, p1-18. 18p.

Developing generic templates to shape the future for conducting integrated research platform trials.

Authors: Gidh-Jain, Madhavi Parke, Tom König, Franz et al.

Source: Trials. 3/21/2024, Vol. 25 Issue 1, p1-12. 12p.

A framework for assessing the impact of accelerated approval.

Authors: Gould AL Campbell RK Loewy JW et al.

Source: PloS one [PLoS One] 2022 Jun 24; Vol. 17 (6), pp. e0265712. Date of Electronic Publication: 2022 Jun 24 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Optimal futility stopping boundaries for binary endpoints.

Authors: Freitag, Michaela Maria Li, Xieran Rauch, Geraldine

Source: BMC Medical Research Methodology. 3/28/2024, Vol. 24, p1-10. 10p.

Built-in selection or confounder bias? Dynamic Landmarking in matched propensity score analyses.

Authors: Strobel, Alexandra Wienke, Andreas Gummert, Jan et al.

Source: BMC Medical Research Methodology. 12/21/2024, Vol. 24 Issue 1, p1-15. 15p.

A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial.

Authors: Mahar, Robert K. McGlothlin, Anna Dymock, Michael et al.

Source: Trials. 12/6/2023, Vol. 24 Issue 1, p1-15. 15p.

Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Authors: Lund, Lars H. Lam, Carolyn S.P. Pizzato, Patricia E. et al.

Source: European Journal of Heart Failure. Sep2023, Vol. 25 Issue 9, p1696-1707. 12p. 1 Color Photograph, 5 Charts, 1 Graph.

The continual problem of crossing survival curves in clinical trial analysis and methods for effectively addressing it: A narrative review.

Authors: Beis, George Papasotiriou, Ioannis

Source: Cancer Research, Statistics & Treatment. Oct-Dec2025, Vol. 8 Issue 4, p276-285. 10p.

Covariate-adjusted response-adaptive designs for semiparametric survival models.

Authors: Mukherjee, Ayon Jana, Sayantee Coad, Stephen

Source: Statistical Methods in Medical Research. Sep2025, Vol. 34 Issue 9, p1697-1723. 27p.

A nationwide, population‐based study on specialized care for acute heart failure throughout the COVID‐19 pandemic.

Authors: Cannata, Antonio Mizani, Mehrdad A. Bromage, Daniel I. et al.

Source: European Journal of Heart Failure. Jul2024, Vol. 26 Issue 7, p1574-1584. 11p.

Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials.

Authors: Pericàs, Juan M. Di Prospero, Nicholas A. Anstee, Quentin M. et al.

Source: Alimentary Pharmacology & Therapeutics. May2023, Vol. 57 Issue 9, p948-961. 14p. 1 Color Photograph, 3 Diagrams, 5 Charts.

Prediction-powered inference for clinical trials: application to linear covariate adjustment.

Authors: Poulet, Pierre-Emmanuel Tran, Maylis Tezenas du Montcel, Sophie et al.

Source: BMC Medical Research Methodology. 8/29/2025, Vol. 25 Issue 1, p1-17. 17p.

Bringing optimised COVID-19 vaccine schedules to immunocompromised populations: statistical elements and design.

Authors: Dymock, Michael McMahon, James H. Griffin, David et al.

Source: Trials. 7/25/2025, Vol. 26 Issue 1, p1-12. 12p.

Limitations of using COX proportional hazards model in cardiovascular research.

Authors: Jiang, Nan Wu, Yongfa Li, Chengjia

Source: Cardiovascular Diabetology. 6/26/2024, Vol. 23 Issue 1, p1-2. 2p.

Statistical considerations for evaluating treatment effect under various non-proportional hazard scenarios.

Authors: Zhang, Xinyu Greene, Erich J Blaha, Ondrej et al.

Source: Statistical Methods in Medical Research. May2025, Vol. 34 Issue 5, p986-1000. 15p.

Sequential Monitoring of Clinical Trials with Weighted Logrank Test in the Presence of Random Delayed Treatment Effect.

Authors: Chen X Zhong S Wang L

Source: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2026 Mar; Vol. 60 (2), pp. 534-543. Date of Electronic Publication: 2025 Nov 26.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101597411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2168-4804 (Electronic) Linking ISSN: 21684790 NLM ISO Abbreviation: Ther Innov Regul Sci Subsets: MEDLINE; In Process

Methodological insights from the EPISTOP trial to designing clinical trials in rare diseases—A secondary analysis of a randomized clinical trial.

Authors: Wied, Stephanie Hilgers, Ralf-Dieter Heussen, Nicole et al.

Source: PLoS ONE. 12/3/2024, Vol. 19 Issue 12, p1-14. 14p.

Optimizing Trial Designs for Targeted Therapies.

Authors: Ondra T Jobjörnsson S Beckman RA et al.

Source: PloS one [PLoS One] 2016 Sep 29; Vol. 11 (9), pp. e0163726. Date of Electronic Publication: 2016 Sep 29 (Print Publication: 2016).

Publication Type: Journal Article

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: PubMed not MEDLINE

Examining evidence of time-dependent treatment effects: an illustration using regression methods.

Authors: Jachno, Kim M. Heritier, Stephane Woods, Robyn L. et al.

Source: Trials. 10/6/2022, Vol. 23 Issue 1, p1-14. 14p. 1 Chart, 5 Graphs.

Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases.

Authors: del Álamo, Marta Bührer, Christoph Fisher, Dirk et al.

Source: Trials. 9/15/2022, Vol. 23 Issue 1, p1-10. 10p. 3 Charts.